Skip to content
News
Data
Podcast
Clinics
EVENTS
News
Data
Podcast
Clinics
EVENTS
Search
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
Advertise
NEWSLETTER
News
Data
Podcast
Clinics
EVENTS
News
Data
Podcast
Clinics
EVENTS
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
Investment
Biotech
Research
AI/Tech
Supplements
Clinics
Ecosystem
LT Wire
About
Contact
About
Contact
Advertise
nEWSLETTER
Search
Search
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Life Biosciences
Biotech
Cellular rejuvenation reaches a human trial
Biotech
Life Bio reaches first clinical milestone for OSK therapy
Investment
Investment
Life Biosciences lands $80m to push cell reset therapy
Biotech
FDA clears first human trial of epigenetic reprogramming therapy
Ecosystem
Interviews of 2025: The innovators
Biotech
Investment
Investment
Longevity biotech activity ‘outpacing’ other segments
Biotech
Life Bio: epigenetic rejuvenation ‘transcends organs’
Biotech
Research
New research collaboration targets cellular rejuvenation
Biotech
Life Bio ready for world’s first partial epigenetic reprogramming trials
The latest longevity science, investment, innovation and insight, delivered every morning.
First Name
(Required)
Email Address
(Required)
Contact Source
Unlock Longevity Biotech Report for FREE
$617BN - Annual global revenue by 2045
$30BN+ - Invested in under 2 years
3,036 - Therapeutics individually assessed
Access full report
